C4 Therapeutics, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders using its TORPEDO platform. It had no approved products and generated no product-sales revenue; reported revenue came from collaborations.
Financial highlights
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Collaboration revenue | $8.5m | $8.4m | $25.7m | $24.9m |
| Research and development expense | $24.3m | $23.9m | $68.1m | $58.0m |
| General and administrative expense | $8.5m | $2.9m | $24.5m | $8.5m |
| Operating loss | $24.3m | $18.3m | $66.9m | $41.5m |
| Net loss | $24.7m | $21.8m | $68.2m | $44.5m |
| Operating cash used | — | — | $61.3m | $45.7m |
Q3 collaboration revenue was nearly flat year over year; nine-month revenue increased about 3%. Nine-month net loss widened by $23.7m. The company reported no product-sales revenue and no meaningful product gross margin; conventional product-margin performance is therefore not applicable.
- Liquidity: Cash, cash equivalents and marketable securities totaled approximately $480.3m at September 30, 2021, including $162.7m cash and equivalents and $317.5m marketable securities. Current assets were $412.3m versus current liabilities of $48.7m.
- Cash flow: Nine-month investing cash use was $129.9m, principally reflecting net purchases of marketable securities; financing provided $170.9m, mainly from the June follow-on offering.
- Debt: Related-party debt carrying value was $10.6m; $12.5m principal was outstanding. The loan bears a variable rate of 11.25% at period-end, is secured by substantially all assets, and matures June 2024. Interest-only payments continue through December 2022; a $3.1m prepayment fee was disclosed.
- Equity: The June 2021 follow-on offering generated $169.5m net proceeds. Shares outstanding were 48.6m at September 30, versus 43.1m at December 31, 2020.
Material changes and operating developments
- R&D expense rose $10.1m for the first nine months, mainly due to personnel costs, including increased stock-based compensation, and clinical-trial costs following CFT7455’s trial launch.
- G&A expense rose $16.0m for the first nine months, largely from higher personnel and stock-based compensation costs and increased public-company professional fees.
- Revenue mix shifted across partners: nine-month Biogen revenue increased to $9.6m from $6.8m, while Calico revenue declined to $8.6m from $10.7m; Roche revenue was approximately unchanged at $7.4m.
- In June 2021, the company began a Phase 1/2 trial of CFT7455; sites were open and enrolling. The FDA granted CFT7455 orphan drug designation for multiple myeloma in August.
- Calico extended the research term for one program to March 2023, generating a $1.0m extension payment. The filing also reports a $1.0m Calico milestone recognized in revenue during the first nine months.
- After quarter-end, on November 9, 2021, C4 Therapeutics and Roche terminated their collaboration for BRAF, making it a proprietary program for C4 Therapeutics and leaving four Roche targets.
Outlook, risks and other notable matters
- Management expected cash, cash equivalents and marketable securities to fund operations for at least 12 months from issuance of the financial statements. Elsewhere in MD&A and the risk factors, the company stated it believed available funds plus expected collaboration payments would fund its existing plan for at least 24 months. These runway statements differ and should be reconciled; the company also cautioned that funds would not finance all candidates through approval.
- Management expects significant ongoing losses and increasing R&D spending as programs advance, and says additional financing will be needed. Future funding may require equity, debt, collaborations or licensing, with potential dilution or concessions of rights.
- Development milestones disclosed: CFT8634 IND submission targeted by year-end 2021 and Phase 1/2 trial in 2022; CFT8919 IND targeted for mid-2022 and trial by year-end 2022; CFT1946 IND targeted for 2022 and trial by year-end 2022. These are forward-looking plans, not guarantees.
- Key risks include the early and unproven nature of targeted protein degradation, clinical and regulatory failure, reliance on third-party manufacturers and research organizations, collaboration-partner decisions, competition, intellectual-property challenges, and COVID-19-related trial, staffing and supply-chain disruptions. The company reported site activation and enrollment delays and prior CRO and manufacturing disruptions.
- The filing identified no material legal proceedings. Management concluded disclosure controls were effective as of September 30, 2021 and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Reconcile the stated 12-month versus 24-month cash runway assumptions and monitor cash burn against the development plan.
- Track CFT7455 enrollment, safety and efficacy updates, and whether planned IND and trial timelines for other candidates are achieved.
- Assess the sustainability and timing of collaboration revenue, milestones and any future partner payments, particularly following the BRAF program’s return to C4 Therapeutics.
- Monitor R&D and stock-based compensation growth, potential future dilution, and the terms and covenants of the related-party secured debt.
- Evaluate whether manufacturing capacity, supply continuity, and COVID-19-related operational risks affect development timelines or costs.